BL-M14D1 + atezolizumab: how does a DLL3 ADC that is “cash-rich but treading on others’ heels” take on 1L small cell lung cancer?

First, know the holder. Biokin (688506.SH) and its US subsidiary SystImmune are no longer the typical biotech “kept alive by the next financing round”. Its flagship asset BL-B01D1 (an EGFR×HER3 bispecific ADC) was licensed to BMS in 2023: US$800 million upfront, up to US$500 million in near-term contingent payments, plus up to US$7.1 billion in milestones, up to US$8.4 billion in total — one of the largest single deals in the history of Chinese innovative drugs going global.

The financial effect of this money is plain to see: in 2024 the company had revenue of RMB 5.823 billion and net profit of RMB 3.708 billion, its first annual profit; in Q3 2025 it recognized another US$250 million milestone from BMS, with quarterly revenue of RMB 1.895 billion and net profit attributable to shareholders of RMB 623 million. Of course, stripping out milestones to look at underlying operations, net profit attributable to shareholders excluding non-recurring items in H1 2025 was still −RMB 1.176 billion — dual-track clinical programs burn real money. But the conclusion is clear: cash is not this company’s current constraint. It has 15 innovative drugs in the clinic and 3 in Phase 3 registration — a genuine “platform + simultaneous global” player.

BL-M14D1 is another bullet on this platform: an antibody–drug conjugate targeting DLL3, with the topoisomerase I inhibitor brengitecan as warhead, sharing the same linker–toxin platform as BL-B01D1. Its indications are small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) broadly. The China Phase 1 (NCT06505824), sponsored by Sichuan Baili, started in August 2024 at Shanghai East Hospital; the US Phase 1 (NCT07080242), sponsored by SystImmune, started in April 2025 with 19 US sites. China and the US on two tracks, in parallel from day one.

The “another bullet” positioning matters, because it determines the mindset with which BL-M14D1 should be viewed. It shares the linker–toxin platform already validated by BL-B01D1, the same ADC process and cross-border R&D system, so its R&D cost is marginal and the cost of failure can be diversified — for a platform company with more than a dozen pipelines, BL-M14D1 is a bet where “winning is icing on the cake and losing does no serious harm”, not a lifeline staked with everything. This structure precisely allows all its later strategic choices to be calmer and less attached: differentiate where it should, license where it should, with no need to tough it out in a crowded race for the sake of face.

The China Phase 1 data presented at ASCO 2026 (June 1, 2026) covered 127 patients with advanced solid tumors (87 SCLC and 40 NEC), all previously treated, with doses escalating from 0.66 to 6.0 mg/kg every three weeks. The most watched numbers:

This is a competitive early signal. But to place it honestly in the coordinate system, three things cannot be glossed over:

First, it is not “China’s first DLL3 ADC”. Zai Lab, also from China, has a DLL3 ADC, zocilurtatug pelitecan (formerly ZL-1310), likewise using a topoisomerase I warhead and clearly further ahead — it has already started a global Phase 3 registration study in second line and beyond, and first line and NEC are also advancing toward registration in 2026. By the ASCO 2025 figures, ZL-1310 in second line at 1.6 mg/kg had a confirmed response rate of 57% (n=14; 79% unconfirmed), with an overall response rate of 68% in dose escalation. In other words, Zai Lab achieved efficacy of a similar magnitude at a lower dose (1.6 vs 4.0 mg/kg).

Second, “similar efficacy at a lower dose” is a question of therapeutic window. BL-M14D1 needs 4.0 mg/kg to push the response rate to about 62%, accompanied by hematologic toxicity, 1 case of ILD and 1 treatment-related death. Zai Lab’s safety figures are also evolving — at ASCO 2025, grade ≥3 treatment-related adverse events at ≤2.0 mg/kg were about 6%, while the October 2025 update showed about 13% in the 1.6 mg/kg arm, indicating the low dose is not cost-free either. But which has the wider therapeutic index remains the real decider in this “best-in-class” contest, and BL-M14D1 is currently the side that has to prove itself.

Third, brain metastasis data are missing. About half of small cell lung cancers metastasize to the brain, and intracranial activity is almost a mandatory question for assets in this tumor type. Zai Lab disclosed quite striking intracranial data at AACR 2026 (confirmed intracranial response rate of 62.5% in SCLC patients with brain metastases), while BL-M14D1 currently has no public intracranial data — a gap that must be filled as soon as possible.

A positive comparison is worth adding: the DLL3/CD3 bispecific tarlatamab had a response rate of about 40% and median duration of response of about 9.7 months in its pivotal study DeLLphi-301, and won full approval on an overall survival advantage of 13.6 vs 8.3 months (DeLLphi-304, second line vs chemotherapy). On raw response rate numbers, both BL-M14D1 and Zai Lab’s ADC are clearly above the bispecific — a shared advantage of the ADC approach (deeper and faster responses). But remember: the bispecific holds the hardest card, overall survival, while both ADCs currently have only response rates and early progression-free survival. Whether high response rates can be converted into survival benefit is a proposition the whole ADC camp still has to prove.

On demand there is no dispute. China had about 159,100 new cases of small cell lung cancer in 2022, about 70% of them extensive-stage, i.e. about 110,000 extensive-stage patients a year; this is a highly malignant tumor that metastasizes early, with historical overall two-year survival in extensive stage of only about 8% (varying considerably by stage and treatment era). DLL3 is highly expressed in SCLC (about 85%–94%), and — an often overlooked positive — DLL3 therapies currently do not require a companion diagnostic, so there is no testing-penetration hurdle to commercialization.

The problem is that the “door” is already guarded:

• First line (1L): long since the domain of “chemotherapy + immunotherapy”. Atezolizumab (Tecentriq, approved February 2020, IMpower133 regimen), durvalumab and domestic serplulimab, among others, are already in place.
• Second line: before tarlatamab, second line already had cytotoxic options such as topotecan and lurbinectedin (whose mechanism is related to the ADC warhead), of limited efficacy but established by habit; now add an approved DLL3 bispecific, and second line will only get more crowded.
• Later lines: the DLL3/CD3 bispecific tarlatamab (Imdelltra) received conditional approval in China on April 10, 2026 for extensive-stage SCLC after failure of at least two prior lines (including platinum), the first DLL3/CD3 T-cell engager approved in China, co-commercialized by BeiGene and Amgen.

This means BL-M14D1 faces a pincer in China: if it goes to later lines, tarlatamab is already marketed and Zai Lab’s ADC is ahead in a global second-line Phase 3; if it goes to first line, it has to face the high wall of “chemo + immunotherapy”, where the registration bar is highest. BL-M14D1’s choice to put its global registration study in 1L ES-SCLC is right in direction — it is the only high-value space not yet occupied by a DLL3 asset — but it is also the hardest road.

Laying out the whole DLL3 race makes BL-M14D1’s position more intuitive:

Note: Data in the table come from each company’s public disclosures, from different trials, doses, lines and follow-up; for landscape reference only, not equivalent to head-to-head comparison.

This table shows two things: first, DLL3 has shifted from “is there a drug” to “how crowded is it” — one marketed bispecific, one leading same-class ADC, one bispecific in global Phase 3, plus a long queue of Phase 1 DLL3 ADCs from Hengrui, Innovent, CSPC and others; second, competition has already escalated to the level of combinations — Boehringer Ingelheim and Zai Lab have teamed up to explore a “bispecific + ADC” dual-DLL3 combination. BL-M14D1’s attempt to carve a new path with “ADC + atezolizumab” is not uncharted territory either.

Picking out the “hard conditions” on which this asset stands or falls:

Reading these gates together actually points to a more fundamental judgment: BL-M14D1’s real moat candidate is not the “DLL3” target (the target is public and already crowded), but “the experience difference of the ADC approach relative to bispecifics”. Although tarlatamab launched first and has overall survival data, it requires patients to be hospitalized for observation around the first doses and managed for cytokine release syndrome and neurotoxicity, which is not friendly to primary-care and outpatient settings; an ADC is a single intravenous infusion with patients returning to hospital per cycle, easier for both physicians and patients. In a real world where patients’ performance status is generally poor and travel distances to care are long, “easier to use” is itself clinical value. If BL-M14D1 wants to stand up, its differentiation story should be built around “hitting DLL3 too, but safer, simpler, and able to pair with immunotherapy”, rather than competing with the bispecific on response rate — a dimension where it can’t win much and can’t hold.

BL-M14D1 was designed from the start as a “China–US simultaneous development” asset: Chinese and US Phase 1 trials in parallel, with global rights fully retained (unlike BL-B01D1, which was licensed to BMS). The return on this road is retaining full flexibility to self-commercialize global registration or license it as a whole; the cost is dual-track clinical programs, CMC in two places, plus the structural uncertainty of China–US policy (such as biosecurity-related legislation), doubling both cost and risk.

And once “combination with atezolizumab” is placed on this board of simultaneous global development, one judgment surfaces: the main battlefield for this combination is overseas, not China.

The reasons have already been laid out: in China, atezolizumab is not on the NRDL and faces price pressure from domestic immunotherapies, so a “DLL3 ADC + atezolizumab” combination is inherently disadvantaged on the payment side; but in the US and globally, atezolizumab + chemotherapy is already the standard first-line backbone for extensive-stage SCLC, and building around it goes with the flow. And BL-M14D1’s global Phase 3 has precisely put SystImmune as sponsor and uses atezolizumab as the underlying immunotherapy — in effect confirming with real money the judgment that “the main battlefield for the combination is overseas”.

Even more intriguing is the control arm it chose. The control arm of this Phase 3 is not “bare” chemo-immunotherapy but chemotherapy + atezolizumab induction followed by atezolizumab ± lurbinectedin maintenance — that is, it takes the IMforte regimen just approved by FDA in October 2025 (lurbinectedin + atezolizumab maintenance, median overall survival 13.2 vs 10.6 months, progression-free survival 5.4 vs 2.1 months) directly as the yardstick. This means what BL-M14D1 has to beat is a fairly strong current standard that has just been raised.

So the more precise strategic formulation is: use atezolizumab as the combination backbone globally; in China, switch to a domestic PD-(L)1 in a dual-backbone strategy. One molecule, two markets, two sets of partners.

The other side of simultaneous global development is an unavoidable policy question. BL-M14D1 is an asset held by a Chinese company but heavily dependent on US registration and the US market to realize its value, which exposes it directly to the risk of China–US biopharma decoupling — from biosecurity-related legislation to foreign investment reviews, any tightening could change the feasibility of SystImmune self-commercializing in the US. This is exactly where the value of a BD license lies: BL-B01D1 has already demonstrated that a large license-out both monetizes immediately and transfers subsequent global development and commercialization risk (including policy risk) to a multinational. For BL-M14D1, “licensing global or regional rights at the right time” is not only a means of monetization but also insurance against geopolitical uncertainty.

An easily assumed judgment needs correcting here. For a latecomer, the “safe” playbook should have been maintenance therapy following the IMforte template — adding the drug after induction, with progression-free survival as the endpoint, a cleaner comparator and a lower threshold. But SystImmune did exactly the opposite. In the registered Phase 3, the experimental arm is a completely chemotherapy-free “BL-M14D1 + atezolizumab” doublet, going head-on against the current standard of “chemo + immunotherapy induction then maintenance”. This is not a conservative flanking move but a head-on gamble aimed at replacing first-line chemotherapy.

The odds on this gamble have to be looked at from both sides.

The bullish side: although first-line chemotherapy for small cell lung cancer acts fast, it is highly toxic and severely drains patients’ physical condition; if “chemotherapy-free” holds, the clinical value is disruptive — sparing the myelosuppression, hair loss and fatigue of platinum and etoposide, replaced by an ADC providing cell killing plus PD-L1 immune activation. Immunogenic cell death induced by the ADC could also in theory synergize with checkpoint inhibition. If the data hold, this is a much bigger story than “yet another maintenance regimen”.

The bearish side: in first-line small cell lung cancer, “removing platinum” is a notoriously high-risk move — chemo-immunotherapy works fast and hard and has been the hard standard for decades, and the control arm also layers on IMforte maintenance, just approved with an overall survival benefit. Proving “no chemotherapy and not worse, or even better” against a yardstick that has been repeatedly reinforced and just raised is an extremely high bar; moreover, ILD and one treatment-related death already appeared in the single-agent Phase 1, and with chemotherapy removed and PD-L1 added, whether efficacy is sufficient and whether the safety window is stable are both real questions. This is a “win and rewrite the guidelines, lose and lose everything” design, without the cushion a maintenance regimen offers of “step back and still get a small indication”.

Third, the brain is the lifeline. About half of SCLCs metastasize to the brain; whoever can prove good intracranial control will stand firm in the guidelines. The data BL-M14D1 most needs to add now are intracranial responses in a brain metastasis cohort — both filling a gap and a must-win ground directly against Zai Lab.

Fourth, the payment reality. First-line SCLC immunotherapy in China is dominated by domestic drugs + NRDL coverage, leaving limited room for a combination of a high-priced ADC + imported immunotherapy. This further confirms that the Chinese market is better suited to “a domestic immunotherapy partner + a differentiated later-line/maintenance position”, while the ambition of “combining with atezolizumab to charge first line” should be realized overseas.

Fifth, don’t forget the second curve beyond SCLC. DLL3 is highly expressed not only in small cell lung cancer but also accessible in neuroendocrine carcinomas broadly — neuroendocrine prostate cancer, gastroenteropancreatic neuroendocrine carcinoma, large cell neuroendocrine lung carcinoma, Merkel cell carcinoma and others. BL-M14D1’s US Phase 1 has already included these pan-neuroendocrine tumor types in enrollment (40 of 127 patients were NEC). Each of these tumor types is small on its own, but together they form a blue ocean with almost no standard therapy, and competitive intensity is far lower than in SCLC. For an asset positioned behind in SCLC, pan-neuroendocrine carcinoma may be a more comfortable battlefield for differentiation — there, the disadvantage of “arriving late” will be much smaller.

As an ADC, BL-M14D1 cannot avoid batch-to-batch consistency of the conjugation process (stability of the warhead-to-antibody ratio), complex characterization and relatively high manufacturing costs — the latter will further squeeze its already limited pricing margin in China. But the upside is that the brengitecan warhead is an in-house platform asset, toxin supply and related IP are relatively controllable, and the whole ADC process has been repeatedly honed on sister assets such as BL-B01D1. What needs vigilance is freedom-to-operate (FTO) risk in a crowded race: the linker/warhead space for DLL3 ADCs is getting denser, and a pre-launch FTO review cannot be skipped.

There is also an often-underestimated advantage hidden here: because it shares a platform with BL-B01D1, BL-M14D1 hardly needs to invest again in “building a new ADC production line”. The same conjugation process, the same quality control system and the same toxin supply are amortized over multiple assets — exactly the compounding CMC advantage of a “platform company” over a single-product biotech: a single-product company pays tuition from scratch for each ADC, while a platform company spends one tuition payment on a whole string of molecules. This is also why, even though BL-M14D1 is behind in clinical position, its cost of “carrying on” remains controllable.

Put the key milestones on one timeline and the contradiction is plain:

November 2025: tarlatamab receives full approval in the US (second-line SCLC);

April 10, 2026: tarlatamab receives conditional approval in China (later line);

From 2025: Zai Lab’s ZL-1310 global Phase 3 under way, first line advancing toward registration;

June 2026: at the same time as BL-M14D1 presented Phase 1 data, its global Phase 3 (NCT07625644) was registered on June 4 and expected to start this month, with the primary endpoint (BICR-PFS) expected to reach primary analysis in January 2030.

The conclusion is direct: this company isn’t short of money; it is short of time. While competitors are already harvesting registration readouts, BL-M14D1 is still at the starting line of its registration study. Fortunately, ample cash gives it two affordable choices — either spend money to buy speed and differentiate, or decisively license and monetize when valuation is high and data are positive. It does not have to choose between “toughing it out” and “selling cheap”.

So what is the “license and monetize” road worth? No precise valuation here, just one anchor: DLL3 ADCs are one of the hottest oncology asset classes right now, Zai Lab’s same-class leader has pushed attention on this race very high, and Biokin’s own BL-B01D1 has just demonstrated a ceiling for Chinese ADCs going global of “US$800 million upfront and up to US$8.4 billion in total”. Even with only Phase 1 data, BL-M14D1, with the combination of the DLL3 ADC label + a 62% response rate + fully intact global rights, still has considerable deal appeal. The most rational timing is while Phase 1 data are positive and before the global Phase 3 trials have really decided a winner — when uncertainty can still support a high-premium story; once competitors’ Phase 3 survival data land first, BL-M14D1’s bargaining power will only be squeezed further. In other words, the earlier the BD card is played, the more it is worth.

BL-M14D1 is a classic “good asset, bad position”: a confirmed response rate of about 60% proves it has cards to play, and DLL3 was long ago validated as a real target by tarlatamab; but it sits in a race that is already crowded, with someone running ahead — the most advanced same-class competitor achieved similar efficacy at a lower dose and entered global Phase 3 earlier. Its greatest source of confidence is not the molecule itself but the platform company behind it, fed full by US$8.4 billion and holding 15 pipelines — which makes “rewriting the first-line standard with a chemotherapy-free combination” an affordable ambition, and “exiting via a timely license” a respectable alternative. For Biokin, the real question BL-M14D1 has to answer is not “can it produce data”, but “in a race where others are already ahead, should it use money to buy speed, or use data to exchange for a well-priced exit ticket”.